WTX-330
Phase 1/2Active 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced or Metastatic Solid Tumors
Conditions
Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma
Trial Timeline
May 7, 2025 → Aug 1, 2028
NCT ID
NCT06939283About WTX-330
WTX-330 is a phase 1/2 stage product being developed by Werewolf Therapeutics for Advanced or Metastatic Solid Tumors. The current trial status is active. This product is registered under clinical trial identifier NCT06939283. Target conditions include Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma.
What happened to similar drugs?
16 of 20 similar drugs in Advanced or Metastatic Solid Tumors were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
9
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06939283 | Phase 1/2 | Active |
| NCT05678998 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced or Metastatic Solid Tumors